Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infection in women

With reference to the article by van Valkengoed et al ,1 we would like to express our views. We agree with the authors' statement that systematic screening of all women aged 15–40 years for asymptomatic Chlamydia trachomatis infection is not cost effective, especially when the prevalence of infection in Amsterdam is low (2.2%–2.8%). Not all countries have achieved such …